biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by rustycaton May 01, 2019 3:42pm

66 Views

Post# 29696713

RE:RE:RE:RE:RE:Consillium Healthcare Newsw letter.

digi,

It's still the FDA, between the responsibility to protect the public health and to protect the profits of large pharma there can be unimagineable hoops to jump through---just ask every other biotech that has had it's experts and management plan a campaign to seek approval.

Bullboard Posts

Rich TV Live’s Stocks to Watch this week (Nov. 15, 2024)